Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-213 in Healthy Adult Participants
NCT06968338Phase 1Completed
- Sponsor
- argenx
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ARGX-213 with Placebo (2 arms). Primary endpoint: Incidence of adverse events, serious adverse events, and adverse events leading to discontinuation at 17 weeks. Started Apr 2025; status: completed.
02
Drugs
ARGX-213
Beyond the preview
Go deeper on NCT06968338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968338.